Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma

BACKGROUND: Midazolam (MDZ) is an anaesthetic that is widely used for anxiolysis and sedation. More recently, MDZ has also been described to be related to the outcome of various types of carcinomas. However, how MDZ influences the progression of hepatocellular carcinoma (HCC) and its effects on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Junwei, Zheng, Zhiying, Li, Xian, Huang, Tian, Rong, Dawei, Liu, Xinyang, Qin, Miaomiao, Wang, Yuliang, Kong, Xiangyi, Song, Jinhua, Lv, Chengyu, Pan, Xiongxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555186/
https://www.ncbi.nlm.nih.gov/pubmed/36224624
http://dx.doi.org/10.1186/s12935-022-02735-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555186/
https://www.ncbi.nlm.nih.gov/pubmed/36224624
http://dx.doi.org/10.1186/s12935-022-02735-3

Ejemplares similares